-
Mashup Score: 0Study Characterizes Enhanced Functionality of Low-Affinity CD19 CAR T-Cell Products | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination January 26, 2023 Enhanced functionality of low-affinity T cells expressing a chimeric antigen receptor (CAR) targeting CD19 (CAT) is a result of an antigen-dependent priming caused by residual CD19-expressing…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Tip Sheet: New study on disparities in COVID-19 clinical trials, how microbes help cancer, research updates on HIV/AIDS — and follow us at ASH - 1 year(s) ago
SEATTLE — Dec. 6, 2022 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the 64th American Society of Hematology Annual Meeting and Exposition (ASH), see our media tip sheet to learn about what our researchers will present on COVID-19 and cancer, CD19 CAR T-cell therapy and precision oncology, and follow Fred Hutch on Twitter at…
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Tip Sheet: New study on disparities in COVID-19 clinical trials, how microbes help cancer, research updates on HIV/AIDS — and follow us at ASH - 1 year(s) ago
SEATTLE — Dec. 6, 2022 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the 64th American Society of Hematology Annual Meeting and Exposition (ASH), see our media tip sheet to learn about what our researchers will present on COVID-19 and cancer, CD19 CAR T-cell therapy and precision oncology, and follow Fred Hutch on Twitter at…
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Multiple alternative splicing events in CD19 mRNA have been associated with resistance/relapse to CD19 CAR-T therapy in patients with B cell malignancies. Here, by combining patient data and a high-throughput mutagenesis screen, the authors identify single point mutations and RNA-binding proteins that can control CD19 splicing and be associated with CD19 CAR-T therapy resistance.
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The outcomes for children/young adults with relapsed/refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL) remain dismal [1,2]. Response and durable remission have been achieved with autologous CD19-specific chimeric antigen receptor (CAR) T cells, creating new opportunities for long-term survival in this patient population [3,4]. Following collection of patient T cells, CAR T cell…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Akinao Okamoto, Hidetsugu Fujigaki, Chisako Iriyama, Naoe Goto, Hideyuki Yamamoto, Keichiro Mihara, Yoko Inaguma, Yasuo Miura, Katsuya Furukawa, Yukiya Yamamoto
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.
Source: Nature MedicineCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies - 3 year(s) ago
Ortiz-Maldonado and colleagues evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells incorporating A3B1, a novel anti-CD19), in 47 adult and pediatric patients with relapsed/refractory CD19+ malignancies. The efficacy was comparable with other academic or commercially available products, while safety was improved with the fractionated administration of cells.
Source: Molecular TherapyCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
Nirali Shah, MD, National Cancer Institute, Bethesda, MD, discusses the findings of a retrospective evaluation of the impact of blinatumomab…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The enhanced functionality of low-affinity #Tcells expressing a #CAR targeting #CD19 is a result of an antigen-dependent priming caused by residual CD19-expressing B cells present in the manufacture, according to a recent @BloodAdvances study https://t.co/jVbSqQIuaZ